Walleye Capital’s Epizyme, Inc EPZM Stock Holding History

Walleye Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-35,478	Closed	-$89K	–	2799
2021 Q4	$89K	Buy	+35,478	New	+$139K	﹤0.01%	1710

Other funds holding EPZM

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's EPZM Position: Q1 2022 in Review

Walleye Capital sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 35,478 shares — an estimated $89K sold.

Walleye Capital first reported a position in EPZM in Q4 2021 and held it in 1 quarter. The position peaked at $89K in Q4 2021. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

Walleye Capital reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 35,478 Epizyme, Inc shares in Q1 2022, an estimated $89K.
Walleye Capital first reported a position in Epizyme, Inc in Q4 2021 and held it in 1 quarter.
Walleye Capital's Epizyme, Inc position peaked at $89K in Q4 2021.
120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.